868 related articles for article (PubMed ID: 27919028)
1. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
2. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
4. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
5. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
6. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
7. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
11. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
Wang LJ; Wang SG; Deng TX
Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
[TBL] [Abstract][Full Text] [Related]
12. Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K/AKT signaling.
He LF; Xu HW; Chen M; Xian ZR; Wen XF; Chen MN; Du CW; Huang WH; Wu JD; Zhang GJ
Oncotarget; 2017 Mar; 8(11):17573-17585. PubMed ID: 28407679
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
14. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
15. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
16. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.
Wang Y; Chen L; Huang G; He D; He J; Xu W; Zou C; Zong F; Li Y; Chen B; Wu S; Zhao W; Wu J
PLoS One; 2013; 8(2):e57391. PubMed ID: 23437382
[TBL] [Abstract][Full Text] [Related]
17. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
18. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
20. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]